About Etanercept
Class: | Biologic response modifier, Tumor necrosis factor (TNF) inhibitor
Use: | Treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and juvenile idiopathic arthritis
Adult dose: | 50 mg subcutaneously once weekly for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; for plaque psoriasis, initial dose is 50 mg twice weekly for 3 months, then 50 mg once weekly; for juvenile idiopathic arthritis, 0.8 mg/kg (
Drug Class
Biologic response modifier, Tumor necrosis factor (TNF) inhibitor
Uses & Indications
Treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and juvenile idiopathic arthritis
Storage Requirements
Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze; may be stored at room temperature (up to 25°C or 77°F) for up to 14 days before use
Manufacturer & Packaging
Manufacturer: Sandoz GmbH, AUSTRIA
Package Size
1ml Prefilled Syrige x 4
Price & Supplier
Price in UAE: AED 3001.50
Dosage Information
Adult Dose
50 mg subcutaneously once weekly for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; for plaque psoriasis, initial dose is 50 mg twice weekly for 3 months, then 50 mg once weekly; for juvenile idiopathic arthritis, 0.8 mg/kg (up to 50 mg) subcutaneously once weekly
Pediatric Dose
For juvenile idiopathic arthritis, 0.8 mg/kg (up to 50 mg) subcutaneously once weekly, for patients aged 2 years and older
Side Effects
Injection site reactions, headache, upper respiratory infections, nausea, increased risk of infections, and potential for malignancies
Contraindications & Precautions
Active infections (including tuberculosis), hypersensitivity to etanercept or any component of the formulation, and concurrent use with other biologic DMARDs or live vaccines
Important Warnings
Increased risk of serious infections, including tuberculosis; monitor for signs of infection; may cause or exacerbate heart failure; risk of malignancies; caution in patients with a history of demyelinating disorders; avoid use in patients with active or chronic infections.
Related Medicines in Same Category
See also: Other Biologic response modifier, Tumor necrosis factor (TNF) inhibitor medicines available in UAE pharmacies
Etanercept (ERELZI)
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.